- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Mania AND Major Depressive Disorder.
Displaying page 1 of 2.
EudraCT Number: 2009-011253-40 | Sponsor Protocol Number: PQ2 | Start Date*: 2009-04-23 | |||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
Full Title: Paroxetine or Quetiapine in Addition to Mood Stabilizers in Bipolar Depression | |||||||||||||
Medical condition: Major Depressive Episode in Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023740-32 | Sponsor Protocol Number: 2010-023740-32 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Haukeland University Hospital [...] | |||||||||||||
Full Title: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder | |||||||||||||
Medical condition: The goal of this work is to identify genes associated with good response of bipolar patients to two commonly used mood stabilizing agents, lithium and valproate. 1. All patients will be started on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004023-24 | Sponsor Protocol Number: PRETEC-EPO | Start Date*: 2016-12-15 | ||||||||||||||||
Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet | ||||||||||||||||||
Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO) | ||||||||||||||||||
Medical condition: Bipolar disorder and unipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004132-33 | Sponsor Protocol Number: D1050304 | Start Date*: 2013-05-02 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304) | |||||||||||||
Medical condition: Major Depressive Disorder (MDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002020-37 | Sponsor Protocol Number: 20/15 | Start Date*: 2015-09-03 | |||||||||||
Sponsor Name:St Patrick's Mental Health Services | |||||||||||||
Full Title: Ketamine for relapse prevention in recurrent depressive disorder: a randomised, controlled pilot trial | |||||||||||||
Medical condition: Recurrent depressive disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006861-39 | Sponsor Protocol Number: GH001-BD-202 | Start Date*: 2022-06-20 | |||||||||||
Sponsor Name:GH Research Ireland Limited | |||||||||||||
Full Title: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202) | |||||||||||||
Medical condition: Bipolar II Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004357-94 | Sponsor Protocol Number: NPS-2005-1 | Start Date*: 2006-01-20 |
Sponsor Name:Nordfjord Psychiatric Centre | ||
Full Title: Escitalopram in bipolar depression: a placebo-controlled study of acute and maintenance treatment. | ||
Medical condition: Patients with bipolar disorder in a depressive episode are randomised to receive escitalopram or placebo for eight weeks. Responders to escitalopram are re-randomised to placebo or escitalopram for... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005072-32 | Sponsor Protocol Number: R&D2004/39 | Start Date*: 2005-12-19 |
Sponsor Name:Kings College London (IOP) / South London and Maudsley NHS Trust (Co-sponsorship) | ||
Full Title: Is it possible to modify the course of manic relapse? A pilot study of the effectiveness of quetiapine in preventing the development of manic episodes in Bipolar Disorder. | ||
Medical condition: Bipolar Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006706-69 | Sponsor Protocol Number: DUAG9V1.03_10.06.2022 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Psychiatry – Aalborg University Hospital, Unit for Psychiatric Research | |||||||||||||
Full Title: Lithium versus cariprazine in the acute phase treatment of bipolar depression: a pragmatic head-to-head open, randomized multicenter study. The 9th study of the Danish University Antidepressant Gro... | |||||||||||||
Medical condition: Bipolar disorder, current depressive episode. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002108-11 | Sponsor Protocol Number: SEP380-303 | Start Date*: 2022-02-10 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
Medical condition: Major Depressive Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003002-12 | Sponsor Protocol Number: CMIJ821X2201 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharma... | |||||||||||||
Medical condition: Treatment Resistant Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003038-34 | Sponsor Protocol Number: D1002001 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression | |||||||||||||
Medical condition: Bipolar I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000757-13 | Sponsor Protocol Number: RGH-MD-54 | Start Date*: 2016-06-07 | |||||||||||
Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo... | |||||||||||||
Medical condition: Bipolar I Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004764-18 | Sponsor Protocol Number: 01-17 | Start Date*: 2017-07-24 |
Sponsor Name:St Patrick’s Mental Health Services | ||
Full Title: Ketamine as an adjunctive therapy for Major Depression - a randomised controlled pilot trial: The KARMA-Dep Trial | ||
Medical condition: Depression | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000986-10 | Sponsor Protocol Number: D1050296 | Start Date*: 2011-12-14 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE PREVENTION OF RECURRENCE IN SUBJECTS WITH BIPOLAR I DISO... | |||||||||||||
Medical condition: Bipolar disorder I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002055-15 | Sponsor Protocol Number: J81J1100168007 | Start Date*: 2014-01-28 |
Sponsor Name:UNIVERSITY OF SASSARI | ||
Full Title: RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER P... | ||
Medical condition: BIPOLAR I MOOD DISORDERS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001357-10 | Sponsor Protocol Number: TAK-375SL_301 | Start Date*: 2012-11-14 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd (TGRD) | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg a... | |||||||||||||
Medical condition: Acute Depressive Episodes associated with Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002551-17 | Sponsor Protocol Number: 12022A | Start Date*: 2007-12-14 | |||||||||||
Sponsor Name:H. Lundbeck a/s | |||||||||||||
Full Title: Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo i... | |||||||||||||
Medical condition: Bipolar Depression at Phase II study with patients. Lu AA34893 is a novel compound under development by H. Lundbeck A/S as an antidepressant. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Prematurely Ended) FR (Completed) GB (Prematurely Ended) SE (Prematurely Ended) DE (Completed) LT (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000756-98 | Sponsor Protocol Number: RGH-MD-53 | Start Date*: 2016-07-19 | |||||||||||
Sponsor Name:Forest Laboratories LLC, an Allergan Affiliate | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipo... | |||||||||||||
Medical condition: Bipolar I Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004790-31 | Sponsor Protocol Number: 55308942BIP2001 | Start Date*: 2022-05-31 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression | |||||||||||||
Medical condition: Bipolar Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
